We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
p16 promoter methylation, expression, and its association with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 subtype of breast carcinoma.
- Authors
Goyal, Aditi; Sahu, Ram; Kumar, Mohit; Sharma, Sonal; Qayyum, Shariq; Kaur, Navneet; Singh, Usha; Mehrotra, Ravi; Hedau, Suresh; Sahu, Ram Krishna; Singh, Usha Rani
- Abstract
<bold>Objectives: </bold>The purpose of the study is to investigate p16 protein expression and promoter methylation of p16 gene and their association with molecular subtypes based on parameter such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).<bold>Materials and Methods: </bold>A total of 114 breast cancer tissue biopsies were collected for methylation-specific polymerase chain reaction (MSP) and immunohistochemical (IHC) analysis.<bold>Results: </bold>Seven tissue microarrays were constructed. p16 protein expression was studied in 114 cases, of which 35/114 (30.7%) cases showed strong expression and the majority of them had ER-positive tumor (57.6%), and it was statistically significant (P < 0.0074). Similarly, p16 expression was reduced in the majority of PR-negative tumors (83.9%) and the association was statistically significant (P = 0.0026). p16 methylation was studied in 114 cases and was positive in 71.0% cases.<bold>Conclusion: </bold>High p16 protein expression was associated with ER-positive, PR-negative, and HER2-negative tumors which is associated with poor prognosis. p16 protein expression may be used as a prognostic indicator to predict treatment response to hormonal therapy.
- Subjects
EPIDERMAL growth factor receptors; ESTROGEN receptors; PROGESTERONE receptors; HUMAN growth; PROTHROMBIN
- Publication
Journal of Cancer Research & Therapeutics, 2019, Vol 15, Issue 5, p1147
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/jcrt.JCRT_472_18